Helios Imbruvica

In a report published Sunday, UBS analyst Marc Goodman reviewed key data points from the American Society of Clinical Oncology (ASCO). AbbVie: Ph-III Helios Data 'Quite Strong' Goodman noted that AbbVie Inc (NYSE: ABBV)'s data for Helios Imbruvica combo in 2L CLL/SLL was "...